​

Athira Pharma (ATHA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ATHA Stock Forecast

Athira Pharma (ATHA) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $13.33, with a high of $33.00 and a low of $3.00. This represents a 97.48% increase from the last price of $6.75.

- $7 $14 $21 $28 $35 High: $33 Avg: $13.33 Low: $3 Last Closed Price: $6.75

ATHA Stock Rating

Athira Pharma stock's rating consensus is Hold, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 0 Buy (0.00%), 5 Hold (100.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

ATHA Price Target Upside V Benchmarks

TypeNameUpside
StockAthira Pharma97.48%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$4.00
Last Closing Price$6.75$6.75$6.75
Upside/Downside---40.74%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26--2--2
Dec, 25--2--2
Nov, 25--2--2
Oct, 25--2--2
Sep, 25--2--2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 19, 2025Graig SuvannavejhMizuho Securities$4.00$3.834.44%-40.74%
Jun 22, 2022Andrew TsaiJefferies$3.00$2.855.26%-55.56%
Apr 21, 2022Berenberg Bank$33.00$11.63183.75%388.89%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 04, 2024Rodman & RenshawBuyNeutraldowngrade
Sep 04, 2024JMP SecuritiesPerformMarket Performdowngrade
Sep 04, 2024JMP SecuritiesMarket OutperformPerformdowngrade
Sep 04, 2024BTIGNeutralPositivedowngrade
Sep 03, 2024BTIGNeutraldowngrade
Aug 19, 2024Rodman & RenshawBuyinitialise
Oct 17, 2022JMP SecuritiesMarket Outperformupgrade
Jun 22, 2022JefferiesBuydowngrade

Financial Forecast

EPS Forecast

$-35 $-28 $-21 $-14 $-7 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-30.90$-25.20$-24.70---
Avg Forecast$-3.18$-2.42$-1.51$-0.82$-0.84$-1.44
High Forecast$-3.11$-2.42$-1.51$-0.81$-0.80$-1.44
Low Forecast$-3.25$-2.42$-1.51$-0.82$-0.88$-1.44
Surprise %871.70%941.32%1535.76%---

Revenue Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$13.43M--
High Forecast---$13.43M--
Low Forecast---$13.43M--
Surprise %------

Net Income Forecast

$-125M $-106M $-87M $-68M $-49M $-30M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-117.67M$-96.94M$-105.61M---
Avg Forecast$-120.87M$-92.10M$-57.41M$-30.99M$-31.94M$-54.75M
High Forecast$-118.33M$-92.10M$-57.41M$-30.80M$-30.55M$-54.75M
Low Forecast$-123.41M$-92.10M$-57.41M$-31.18M$-33.33M$-54.75M
Surprise %-2.65%5.25%83.95%---

ATHA Forecast FAQ

Is Athira Pharma stock a buy?

Athira Pharma stock has a consensus rating of Hold, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 0 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Athira Pharma is a neutral investment for most analysts.

What is Athira Pharma's price target?

Athira Pharma's price target, set by 5 Wall Street analysts, averages $13.33 over the next 12 months. The price target range spans from $3 at the low end to $33 at the high end, suggesting a potential 97.48% change from the previous closing price of $6.75.

How does Athira Pharma stock forecast compare to its benchmarks?

Athira Pharma's stock forecast shows a 97.48% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Athira Pharma over the past three months?

  • January 2026: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Athira Pharma’s EPS forecast?

Athira Pharma's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.82, marking a -96.68% decrease from the reported $-24.7 in 2025. Estimates for the following years are $-0.84 in 2027, and $-1.44 in 2028.

What is Athira Pharma’s revenue forecast?

Athira Pharma's average annual revenue forecast for its fiscal year ending in December 2026 is $13.43M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $0, and $0 for 2028.

What is Athira Pharma’s net income forecast?

Athira Pharma's net income forecast for the fiscal year ending in December 2026 stands at $-30.986M, representing a -70.66% decrease from the reported $-106M in 2025. Projections indicate $-31.937M in 2027, and $-54.749M in 2028.